Cargando…
Case Report: Atypical HUS Presenting With Acute Rhabdomyolysis Highlights the Need for Individualized Eculizumab Dosing
BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is an ultra-rare orphan disease caused by dysregulated complement activation resulting in thrombotic microangiopathy. Although complement-mediated endothelial injury predominantly affects the renal microvasculature, extra-renal manifestations are...
Autores principales: | Benoit, Stefanie W., Fukuda, Tsuyoshi, VandenHeuvel, Katherine, Witte, David, Fuller, Christine, Willis, Jennifer, Dixon, Bradley P., Drake, Keri A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906567/ https://www.ncbi.nlm.nih.gov/pubmed/35281224 http://dx.doi.org/10.3389/fped.2022.841051 |
Ejemplares similares
-
Case Report: Neonatal Unexplained HUS Treated With Complement Inhibitor Eculizumab
por: Kelen, Dorottya, et al.
Publicado: (2021) -
Use of Eculizumab During Pregnancy in Kidney Transplant Recipients With Atypical HUS
por: Cheung, Chee Kay, et al.
Publicado: (2019) -
A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
por: Rathbone, John, et al.
Publicado: (2013) -
Clinical Relapses of Atypical HUS on Eculizumab: Clinical Gap for Monitoring and Individualised Therapy
por: Teoh, Chia Wei, et al.
Publicado: (2018) -
Remission of aHUS neurological damage with eculizumab
por: Ávila, Ana, et al.
Publicado: (2015)